Xi Chen

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer

Christine M. Lovly, Nerina T. McDonald, Heidi Chen et al. · Nature Medicine · 2014 · 265 citations · Full text

Medicine, Cancer Biology, Co-targeting Igf-1r +7

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Yi‐Long Wu, Ying Cheng, Jianying Zhou et al. · The Lancet Respiratory Medicine · 2020 · 249 citations

Oncology, Met Amplification, Medicine +10

Characteristics of Lung Cancers Harboring <i>NRAS</i> Mutations

Kadoaki Ohashi, Lecia V. Sequist, Maria E. Arcila et al. · Clinical Cancer Research · 2013 · 141 citations · Full text

The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma

Shaodong Hong, Dongbing Liu, Luo Shu-zhen et al. · Nature Communications · 2019 · 124 citations · Full text